We treated the panel of colon cancer cells and their isogenic XPC knock-out (KO) counterparts with oxaliplatin and observed that in 6 out of 10 cell lines XPC loss did not lead to increased sensitivity to oxaliplatin (Figure 1A and Supplementary Figure S2a). This evidence concerns the gene XPC and colonic neoplasm.